Dharani Sathish

Dharani Sathish

Auto-generated profile, based on publicly available information

Dharani Sathish

Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Drug Metabolism and Drug Interactions
Verified
Journal Article
Closed access
YKYamsani Shravan Kumar
Yamsani Shravan Kumar
DADevandla Adukondalu
Devandla Adukondalu
DSDharani Sathish
Dharani Sathish
YVYamsani Vamshi Vishnu
Yamsani Vamshi Vishnu
GRGannu Ramesh
Gannu Ramesh
YRYamsani Madhusudan Rao
Yamsani Madhusudan Rao
P-Glycoprotein (P-gp), the most extensively studied ATP-binding cassette transporter, functions as a biological barrier by extruding toxic substances and xenobiotics out of cells. Drug efflux pumps such as P-gp play a functional role in determining the pharmacokinetics of drugs administered by oral and parenteral routes. Determining the activity of drug efflux transport proteins has important implications in the identification of substrates and/or inhibitors. The significant role of the small intestine in reducing the oral bioavailability of drugs is due to metabolic enzymes and efflux transporters. The role of cytochrome P-450 3A (CYP3A) and P-gp in intestinal drug disposition has been highlighted. This review examines the structure, localisation and functional role of P-gp, the mechanism of drug efflux and drug-herb interactions.

1 September 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TKTahir Khuroo
Tahir Khuroo
SDSathish Dharani
Sathish Dharani
EMEman Mohamed
Eman Mohamed
SISujana Immadi
Sujana Immadi
ZWZhixing Wu
Zhixing Wu
Ziyaur RahmanZiyaur Rahman
Ziyaur Rahman

23 December 2021 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
SDSathish Dharani
Sathish Dharani
KSKhaldia Sediri
Khaldia Sediri
PCPhillip Cook
Phillip Cook
RARajendran Arunagiri
Rajendran Arunagiri
Mansoor A. KhanMansoor A. Khan
Mansoor A. Khan
Ziyaur RahmanZiyaur Rahman
Ziyaur Rahman

1 January 2012 in Archives Of Pharmacy Practice
Verified
Journal Article
Open access
PDF file
MYMadhusudanRao Yamsani
MadhusudanRao Yamsani
SRSunil Reddy
Sunil Reddy
VKVinay Katakam
Vinay Katakam
JSJaganMohan Somagoni
JaganMohan Somagoni
PPPavan Panakanti
Pavan Panakanti
MYMadhusudan Rao Yamsani
Madhusudan Rao Yamsani
Arch Pharma Pract, Official publication of Archives of Global Professionals

1 September 2013 in Current Drug Therapy
Verified
Journal Article
Closed access
PDF file
SHSubedari Himabindu
Subedari Himabindu
DSDharani Sathish
Dharani Sathish
PKPanakanti Pavan Kumar
Panakanti Pavan Kumar
SSShaik Shayeda
Shaik Shayeda
Delivery of hydrophobic drugs via buccal route is a challenging approach. Isradipine (IDP) is a highly hydrophobic drug and is practically insoluble in water. Though the log p value of Isradipine permits the drug to pass through buccal membrane, the amount of drug delivered is low. The aim of present investigation is to develop buccal tablets containing Isradipine complexed with a β-cyclodextrin. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies were used to examine the physicochemical properties of the inclusion complexes. Based on the solubility experiments, the 1:2 molar ratio (Isradipine:β-Cyclodextrin) has given good results. From the photostability studies it was concluded that Isradipine in the inclusion complex was more stable than pure Isradipine. Addition of βCD to the matrix increased the flux by increasing the solubility of drug, thus improving the diffusible form of the drug species at the tablet membrane interface. The flux (FS5) was found to be increased by 1.833 folds with a permeability coefficient of 0.022 cm h-1. Moreover Isradipine undergoes extensive hepatic metabolism. Thus formulating a buccal delivery system of Isradipine with βCD may improve the bioavailability and photostability of the drug along with patient compliance.

31 January 2014 in Current Drug Therapy
Verified
Journal Article
Closed access
PDF file
DSDharani Sathish
Dharani Sathish
SHSubedari Himabindu
Subedari Himabindu
PKPanakanti Pavan Kumar
Panakanti Pavan Kumar
YRYamsani M. Rao
Yamsani M. Rao
Aims: The purpose of this research is to develop a novel expandable gastroretentive dosage form (GRDF), based on an unfolding mechanism. It consists of a drug loaded bilayer polymeric film, folded into a hard gelatin capsule. Gastric retention is achieved due to unfolding of the dosage form within 15-20 min. Captopril is selected as the drug candidate for this work. Due to its narrow absorption window, Captopril has to be administered to the upper parts of the intestine in order to maintain sustained therapeutic levels. This may be achieved by a GRDF. Methodolgy: Films were prepared by solvent-casting technique using Ethyl cellulose, HPMC E15 and Eudragit RLPO as polymers and dibutyl-phthalate as the plasticizer in both layers. The film with zigzag folding in the capsule was shown to unfold in the gastric juice and provide drug release up to 12 h in the acidic medium. The films were evaluated for weight & thickness variation, mechanical properties, in vitro drug release and unfolding behaviour based on the mechanical shape memory of polymers. Absence of drug polymer interaction and uniform drug dispersion in the polymeric layers was revealed by DSC, XRD and SEM studies. The GRDF location in the gastrointestinal tract was determined by X-ray studies. Results: X-ray studies revealed that the GRDF is retained in the stomach up to 6± 0.5 h in fasting condition and 8 h in fed state. Conclusion: The polymers used in the development of GRDFs were safe and proper combination of these polymers will yield a novel expandable GRDF with good in vitro drug release in acidic media, mechanical properties, unfolding behaviour. These outcomes demonstrate that the GRDF may be used to improve Captopril therapy and can be applied to extend the absorption of other narrow absorption window drugs that require continuous input.